Altamira Therapeutics Expands Bentrio License And Distribution Agreement With Nuance Pharma In East And South East Asia
Portfolio Pulse from Benzinga Newsdesk
Altamira Therapeutics has expanded its license and distribution agreement with Nuance Pharma for the Bentrio nasal spray. The agreement now includes seven additional countries in East and South East Asia, with a combined population of over 630 million. Nuance Pharma has already launched Bentrio in Hong Kong and is seeking marketing authorization in Mainland China.
September 16, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altamira Therapeutics (CYTO) has expanded its agreement with Nuance Pharma, increasing the market reach of its Bentrio nasal spray to seven more countries in East and South East Asia. This expansion could significantly boost sales and market presence.
The expansion of the license and distribution agreement with Nuance Pharma to include seven additional countries in East and South East Asia represents a significant market opportunity for Altamira Therapeutics. With a combined population of over 630 million, this expansion could lead to increased sales and market penetration for Bentrio, positively impacting CYTO's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90